The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...

Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and ...

Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.